Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Curigliano

Showing results (31-40 of 190) with videos related to

Pageof 19
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2021
Therapeutic cancer vaccines revamping: technology advancements and pitfallsG Antonarelli, C Corti, P Tarantino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 30, 2014
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer studyX Pivot, J Gligorov, V Müller, et al.
ESMO Open|July 19, 2023
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failureG Antonarelli, C Corti, P Tarantino, et al.
Ecancermedicalscience|January 26, 2012
Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcomaT De Pas, G Spitaleri, P D Vigna, et al.
Ecancermedicalscience|January 26, 2012
QTc prolongation assessment in anticancer drug development: clinical and methodological issuesG Curigliano, G Spitaleri, F de Braud, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 10, 2016
Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?C Criscitiello, G Curigliano, H J Burstein, et al.
The Breast Journal|January 13, 2011
P-170 Glycoprotein (MDR) and p53 Expression in Breast CancerM Ciaparrone, D Terribile, G Curigliano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2012
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesG Curigliano, D Cardinale, T Suter, et al.
ESMO Open|September 6, 2023
Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chainF Roitberg, T Amaral, N I Cherny, et al.
Oncology|June 16, 2001
Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2P Lissoni, M Mandalà, G Curigliano, et al.
Pageof 19

Showing results (31-40 of 190) with videos related to

Sort By:
Pageof 19
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2021
Therapeutic cancer vaccines revamping: technology advancements and pitfallsG Antonarelli, C Corti, P Tarantino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 30, 2014
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer studyX Pivot, J Gligorov, V Müller, et al.
ESMO Open|July 19, 2023
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failureG Antonarelli, C Corti, P Tarantino, et al.
Ecancermedicalscience|January 26, 2012
Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcomaT De Pas, G Spitaleri, P D Vigna, et al.
Ecancermedicalscience|January 26, 2012
QTc prolongation assessment in anticancer drug development: clinical and methodological issuesG Curigliano, G Spitaleri, F de Braud, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 10, 2016
Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?C Criscitiello, G Curigliano, H J Burstein, et al.
The Breast Journal|January 13, 2011
P-170 Glycoprotein (MDR) and p53 Expression in Breast CancerM Ciaparrone, D Terribile, G Curigliano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2012
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesG Curigliano, D Cardinale, T Suter, et al.
ESMO Open|September 6, 2023
Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chainF Roitberg, T Amaral, N I Cherny, et al.
Oncology|June 16, 2001
Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2P Lissoni, M Mandalà, G Curigliano, et al.
Pageof 19